Specialty Respiratory Pipeline


Glenmark’s specialty business is focused on identifying products and formulations that fulfill unique and unmet needs for physician specialists who treat a range of conditions, with our initial efforts focused on respiratory and dermatology. Specialty assets are being commercialized by Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding, SA.

Molecule
Proposed Indication(s)/Indication(s)
MoA/Class
Pre-CLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVAL
RESPIRATORY
RYALTRISTM* NASAL SPRAY (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray, also known as GSP 301)
Seasonal Allergic Rhinitis
Steroid + antihistamine
Seasonal Allergic Rhinitis
Steroid + antihistamine
PHASE 3
GSP 304
COPD
LAMA
COPD
LAMA
Phase 2
GBR 310
Ashthma/CIU
Biosimilar
Ashthma/CIU
Biosimilar
Phase 1
GRC 39815
COPD
RORyt inhibitor
COPD
RORyt inhibitor
Pre-CLINICAL